Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address viral infections, glycovirology, and oxygen delivery, hypoxia and degenerative diseases in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-3, a type of galectin for treatment of mild to moderate cases of Covid-19. Bioxytran, Inc. has collaboration with University of Minnesota for advance novel carbohydrate-based therapeutics. The company was founded in 2008 and is headquartered in Needham, Massachusetts.
Frequently asked questions
What sector does Bioxytran Inc (BIXT) operate in?
Bioxytran Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Bioxytran Inc (BIXT) current stock price?
As of the latest data, Bioxytran Inc stock price is $0.02, with a previous close of $0.02.
What is Bioxytran Inc (BIXT) current market capitalization?
Bioxytran Inc market cap is approximately 2.40 million.
What is Bioxytran Inc (BIXT) Earnings Per Share (EPS)?
The trailing EPS is -$0.02.
Does Bioxytran Inc (BIXT) pay dividends?
No. Bioxytran Inc does not pay a dividend.
What is Bioxytran Inc (BIXT) beta (volatility) score?
Bioxytran Inc has a beta of 1.966, suggesting it is more volatile than the market.
